Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-22T17:15:31.003Z Has data issue: false hasContentIssue false
  • English
  • Français

Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK

Published online by Cambridge University Press:  16 April 2020

J. Borghi  and
J.F. Guest
J. Borghi
Affiliation:
Catalyst Health Economics Consultants Ltd., The Folly, Pinner Hill Road, Pinner, Middlesex, HA5 3YQ, UK
J.F. Guest*
Affiliation:
Catalyst Health Economics Consultants Ltd., The Folly, Pinner Hill Road, Pinner, Middlesex, HA5 3YQ, UK
*
*Correspondence and reprints
Get access

Summary

This study modelled the economic impact of mirtazapine, compared to amitriptyline and fluoxetine, in the management of moderate and severe depression in the UK, as well as the costs related to discontinuation of antidepressant treatment.

Decision models of the management of moderate and severe depression were developed from clinical trial data, resource use obtained from interviews with general practitioners and psychiatrists, and published literature, and were used to estimate the expected direct National Health Service (NHS) costs of managing a patient with moderate or severe depression.

The expected cost of healthcare resource use attributable to managing a patient suffering from moderate or severe depression who discontinues antidepressant treatment, irrespective of the initial treatment, was estimated to be £206 (range £50 to £504) over five months.

Using mirtazapine instead of amitriptyline for seven months increases the proportion of successfully treated patients by 21% (from 19.2 to 23.2%) and reduces the expected direct NHS cost by £35 per patient (from £448 to £413). Using mirtazapine instead of fluoxetine for six months increases the proportion of successfully treated patients by 22% (from 15.6 to 19.1%), albeit for an additional cost to the NHS of £27 per patient (from £394 to £420).

In conclusion, this study suggests that mirtazapine is a cost-effective antidepressant compared to amitriptyline and fluoxetine in the management of moderate and severe depression in the UK.

Keywords

amitriptylinecostsdepressiondropouteconomicsfluoxetinemirtazapineNHS
Type
Original article
Information
European Psychiatry , Volume 15 , Issue 6 , September 2000 , pp. 378 - 387
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Brown, M.C.J., Nimmerrichter, A.A., Guest, J.F.Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria Eur Psychiatry 14 1999 230–244CrossRefGoogle ScholarPubMed
Brown, M.C.J., van Loon, J.M.T., Guest, J.F.Cost-effectiveness of mirtazapine relative to amitriptyline in the treatment of moderate and severe depression in France Eur J Psychiatry 13 1999 197–208Google Scholar
Brown, M.C.J., van Loon, J.M.T., Guest, J.F.Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Eur J Psychiatry 14 2000 15–25Google Scholar
Bruce, N.J., McCloskey, E.V., Kanis, J.A., Guest, J.F.Economic impact of using clodronate in the management of patients with multiple myeloma Br J Haematology 104 1999 358–364CrossRefGoogle ScholarPubMed
Cardot, H., Rouillon, F.The long-term course of depression (epidemiology and clinical aspects) Encephale 21 1995 51–59Google Scholar
Chartered Institute of Public Finance and Accountancy (CIPFA) Health Database. London 1997Google Scholar
Compufile Ltd. Doctors’ Independent Network (DIN-LINK) database. Surrey, England: 1999Google Scholar
Crott, R., Gilis, P.Economic comparisons of the pharmacotherapy of depression: an overview Acta Psychiatr Scand 97 1998 241–252CrossRefGoogle ScholarPubMed
de Boer, T.The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission Int Clin Psychopharmacol 10 1995 19–23CrossRefGoogle ScholarPubMed
Drug tariff. 1998 editions. National Health Service England and WalesGoogle Scholar
Griffin, J.P.The need for pharmacoeconomic evaluations in the NHS Pharmacoeconomics 14 1998 241–250CrossRefGoogle ScholarPubMed
Hamilton, M.A rating scale for depression J Neurol Neurosurg Psychiatry 23 1960 56–62CrossRefGoogle ScholarPubMed
Hirschfeld, R.M.A., Keller, M.B., Panico, S., Arons, B.S., Barlow, D., Davidoff, F. et al. The National Depressive and Manic-Depressive Association Consensus Statement on the Undertreatment of Depression JAMA 277 1997 333–340CrossRefGoogle ScholarPubMed
Kasper, S., Zapotoczky, H.G., Stuppäck, C., König, P., Wuschitz, A.Diagnostik und therapie der depression Neuropsychiatrie 11 1997 S59–S67Google Scholar
Kind, P., Sorenson, J.The costs of depression Int Clin Psychopharmacol 7 1993 191–195CrossRefGoogle ScholarPubMed
Le Pen, C., Levy, E., Ravily, V., Beuzen, J.N., Meurgey, F.The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics J Affect Disord 31 1994 1–18CrossRefGoogle ScholarPubMed
Lépine, J.P., Gastpar, M., Mendlewicz, J., Tylee, A.on behalf of the DEPRES Steering Comittee Depression in the community: the first pan-European study DEPRES (Depression Research in European Society) Int Clin Psychopharmacol 12 1997 19–29CrossRefGoogle Scholar
Marttila, M., Jääskeläinen, J., Järvi, R., Romanov, M., Miettinen, E., SorriP., et al P., et alA double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression Eur Neuropsychopharmacol 5 1995 441–446CrossRefGoogle ScholarPubMed
Montgomery, S.Efficacy in long-term treatment of depression J Clin Psychiatry 57 1996 24–30Google ScholarPubMed
Montgomery, S.A., Brown, R.E., Clark, M.Economic analysis of treating depression with nefazodone v.imipramine Br J Psychiatry 168 1996 768–771CrossRefGoogle Scholar
Montgomery, S.A., Reimitz, P.E., Zivkov, M.Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study Int Clin Psychopharmacol 13 1998 63–73CrossRefGoogle ScholarPubMed
Monthly Index of Medical Specialities (MIMS) 1998 editions. London: Haymarket Publications LtdGoogle Scholar
National Depression Campaign National Depression Campaign Survey London 1999Google Scholar
Netten, A., Dennett, J., Knight, J.Unit costs of health and social carePSSRU University of Kent 1998Google Scholar
Richou, H., Ruimy, P., Charbaut, J., Delisle, J.P., Brunner, H., Patris, M. et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770 Hum Psychopharmacol 10 1995 263–271CrossRefGoogle Scholar
Sowerby Centre for Health Informatics Prodigy Project. Depression: changes to the clinical recommendations. Newcastle University 1999Google Scholar
Stewart, A.Choosing an antidepressant: effectiveness based pharmacoeconomics J Affect Disord 48 1998 125–133CrossRefGoogle ScholarPubMed
The Henley Centre. October 1998. UK Forecasts LondonGoogle Scholar
van Moffaert, M., de Wilde, J., Vereecken, A., Dierick, M., Evrard, J.L., Wilmotte, J. et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalised patients with major depression Int Clin Psychopharmacol 10 1995 3–9CrossRefGoogle Scholar
Weinstein, M.C., Fineberg, H.V.Clinical decision analysis 1980 WB Saunders Co Philadelphia228–265Google Scholar
Weissman, M.M., Bland, R.C., Canino, G.J., Faravelli, C., Greenwald, S., Hwu, H.G. et al. Cross-national epidemiology of major depression and bipolar disorder JAMA 276 1996 293–299CrossRefGoogle ScholarPubMed
Wheatley, D.P., van Moffaert, M., Timmerman, L., Kremer, C.M.E.the Mirtazapine-Fluoxetine Study Group Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder J Clin Psychiatry 59 1998 306–312CrossRefGoogle ScholarPubMed
Zivkov, M., de Jongh, G.D.Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalised depressed patients Hum Psychopharmacol 10 1995 173–180CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.